Showing results (111-120 of 184) with videos related to

Sort By:
Pageof 19
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 8, 2019
High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysisClaudia Kirbs, Franziska Kluwe, Franziska Drescher, et al.
Therapeutic Drug Monitoring|December 31, 2010
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoringArwa Hassan, Jürgen Burhenne, Klaus-Dieter Riedel, et al.
European Journal of Clinical Pharmacology|September 13, 2012
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activityInes Fuchs, Verena Hafner-Blumenstiel, Christoph Markert, et al.
Leukemia|October 28, 2025
Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemiaJochen Greiner, Patrick J Schuler, Hubert Schrezenmeier, et al.
European Journal of Clinical Pharmacology|June 11, 2013
Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1Christoph Markert, Regina Hellwig, Jürgen Burhenne, et al.
British Journal of Clinical Pharmacology|December 17, 2009
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotypeIna Scholz, Heike Oberwittler, Klaus-Dieter Riedel, et al.
Cytokine|December 18, 2020
A nuclear factor kappa B reporter cell line used to evaluate ex vivo the net inflammatory effect of plasma samples from patients with rheumatoid arthritis, psoriasis, or COVID-19Lelia Wagner, Walter E Haefeli, Uta Merle, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 2, 2021
Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?Johanna Weiss, Kathrin Isabelle Foerster, Maria Weber, et al.
The Journal of Antimicrobial Chemotherapy|January 5, 2007
Modulation of human BCRP (ABCG2) activity by anti-HIV drugsJohanna Weiss, Johanna Rose, Caroline Henrike Storch, et al.
British Journal of Clinical Pharmacology|March 27, 2019
Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteersAntonia Brings, Marie-Louise Lehmann, Kathrin I Foerster, et al.
Pageof 19